Why Zimmer Biomet’s latest earnings and leadership changes matter for investors

Zimmer Biomet Holdings (ZBH) has been in focus after Q1 2026 results showed higher sales and net income than a year earlier, alongside a CFO transition and reaffirmed full year revenue guidance.

For the quarter ended March 31, 2026, Zimmer Biomet reported sales of US$2,086.7 million compared with US$1,909.1 million in the same period last year. Net income was US$238.1 million versus US$182 million a year earlier, with basic and diluted earnings per share from continuing operations at US$1.22, compared with US$0.92 and US$0.91 respectively.

At the same time, the company reaffirmed its earnings guidance for 2026, keeping the expected reported revenue change in a 2.5% to 4.5% range. For investors, this guidance provides a numerical reference point for how management is framing the current year after the first quarter results.

The quarter also brought leadership changes. Zimmer Biomet announced that Chief Financial Officer Suketu Upadhyay will depart effective April 28, 2026, for a new professional opportunity. The company appointed Paul Stellato, currently Controller and Chief Accounting Officer, as interim CFO while an internal and external search is conducted for a permanent successor.

Stellato has more than 20 years of broad financial and investor relations experience. Within Zimmer Biomet, he serves as Controller, Chief Accounting Officer and head of Corporate FP&A, and has been involved in capital allocation decisions, including acquisitions and the share repurchase program. His background includes finance leadership roles at Xylem Inc. and ITT Corporation, as well as earlier experience in public accounting at Andersen and Ernst & Young.

Zimmer Biomet’s recent Q1 earnings, CFO transition and ongoing share repurchases come against a softer share price backdrop, with a 30 day share price return of 8.8% decline and a 5 year total shareholder return of 45.9% loss, suggesting momentum has been fading despite recent operational updates.

If Zimmer Biomet’s mix of medical technology and robotics has your attention, it can be useful to compare it with other healthcare related AI opportunities using our curated list of 35 healthcare AI stocks

With the stock down over the past year and trading below the average analyst price target, yet showing recent revenue and net income growth, investors may ask whether Zimmer Biomet is undervalued or whether the market is already pricing in future growth.

Most Popular Narrative: 19% Undervalued

Zimmer Biomet’s most followed narrative pegs fair value at about $103 per share using an 8.81% discount rate, compared with the latest close at $83.37. This frames the current price as materially below that narrative view of long term cash generation.

The company's focused investment in digital health, robotics, and data-driven surgical solutions (including the ROSA and upcoming Monogram platforms) is increasing adoption of premium offerings, enabling margin expansion due to product mix and driving recurring revenues through connected care ecosystems, supporting higher net margins and earnings predictability.

Curious what sits behind that fair value gap? The narrative leans on measured revenue growth, higher margins and a future earnings multiple that many investors might not expect.

Result: Fair Value of $102.95 (UNDERVALUED)

However, this hinges on execution. Setbacks in integrating acquisitions or tougher pricing and reimbursement pressure could quickly challenge that underpriced narrative.

Next Steps

Seeing both concern and optimism in the story so far, it makes sense to check the underlying data now and decide where you stand using our breakdown of 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If Zimmer Biomet has sharpened your focus, do not stop here. Broader opportunities across sectors could help you build a more resilient, well balanced portfolio.

• Spot potential mispricings by scanning 51 high quality undervalued stocks that combine solid fundamentals with room for re rating.
• Strengthen your income stream by reviewing 12 dividend fortresses that target higher yields without ignoring balance sheet quality.
• Get ahead of the crowd by searching screener containing 23 high quality undiscovered gems that pair sound financials with lower market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.